Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome
This study provides Class II evidence that taking ubrogepant 100 mg during a migraine prodrome allows more patients to function normally over the next 24 hours.
Authors
- Richard B. Lipton (ORCID: https://orcid.org/0000-0003-2652-2897)
- Krutika Jariwala‐Parikh
- Pranav Gandhi (ORCID: https://orcid.org/0009-0008-8317-7712)
- Jonathan H. Smith (ORCID: https://orcid.org/0000-0002-2798-6805)
- Andrea M. Harriott (ORCID: https://orcid.org/0000-0003-0417-7586)
- David W. Dodick (ORCID: https://orcid.org/0000-0002-9486-6790)
- Joel M. Trugman (ORCID: https://orcid.org/0000-0002-2376-8878)
- Y. Julia
- Jonathan Stokes
- G. Jensen
Institutions
- Jacobi Medical Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1212/wnl.0000000000209745
- Citations
- 5
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.93